Given its established role in autoimmunity, IL-17A blocking antibodies, such as secukinumab and ixekizumab, have received U.S. Food and Drug Administration (FDA) approval for the treatment of psoriasis, ankylosing spondylitis (AS), and psoriatic arthritis (5). The gene discussed is IL17A; the disease is ankylosing spondylitis.